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Abstract
Background: Recent studies have shown that adult human possess active brown adipose tissue (BAT), which might be
important in controlling obesity. It is known that ß-adrenoceptor-UCP1 system regulates BAT in rodent, but its influence in
adult humans remains to be shown. The present study is to determine whether BAT activity can be independently
stimulated by elevated catecholamines levels in adult human, and whether it is associated with their adiposity.
Methodology/Principal Findings: We studied 14 patients with pheochromocytoma and 14 normal subjects who had
performed both
18F-fluorodeoxyglucose positron emission tomography/computed tomography (
18F-FDG PET/CT) and
plasma total metanephrine (TMN) measurements during 2007–2010. The BAT detection rate and the mean BAT activity were
significantly higher in patients with elevated TMN levels (Group A: 6/8 and 6.762.1 SUVmean? g/ml) than patients with
normal TMN concentrations (Group B: 0/6 and 0.460.04 SUVmean? g/ml) and normal subjects (Group C: 0/14 and 0.460.03
SUVmean?g/ml). BAT activities were positively correlated with TMN levels (R=0.83, p,0.0001) and were inversely related to
body mass index (R=20.47, p=0.010), visceral fat areas (R=20.39, p=0.044), visceral/total fat areas (R=20.52, p=0.0043)
and waist circumferences (R=20.43, p=0.019). Robust regression revealed that TMN (R=0.81, p,0.0001) and waist
circumferences (R=20.009, p=0.009) were the two independent predictors of BAT activities.
Conclusions/Significance: Brown adipose tissue activity in adult human can be activated by elevated plasma TMN levels,
such as in the case of patients with pheochromocytoma, and is negatively associated with central adiposity.
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Introduction
Mammals have two types of adipose tissue that control whole-
body energy metabolism, the well-understood white adipose tissue
for energy storage [1] and brown adipose tissue (BAT) for cold-
and diet-induced thermogenesis [2]. BAT thermogenesis is
dependent on the ß-adrenergically mediated activation of lipolysis
and subsequent degradation of fatty acids via uncoupling protein 1
(UCP1) that dissipate large amounts of chemical energy as heat
[3]. Brown adipose tissue is most obvious in small mammals and
infant humans, but was often believed to be lost postnatally within
the first few years of human life [2]. Recent studies using positron
emission tomography and computed tomography (PET/CT) have
demonstrated that healthy adult humans do possess signifi-
cant depots of metabolically active BAT [4,5,6], which is acutely
cold-induced [5,6] and is inversely correlated with body mass
index (BMI) and age [4,5]. Although several BAT-influencing
factors have been identified [4,5,6], the role of ß-adrenoceptor-
UCP1 system- which is functional in rodents in regulating BAT
activity [2]- has not yet been fully studied in adult humans. In
rodents, it is found that the sensation of cold causes sympathetic
nerve terminals in the brown adipose tissue to release catechol-
amines that stimulate BAT proliferation and activation [2]. In
addition, brown fat activity can be activated by ß-adrenergic
activator or catecholamines, and causes the emergence of UCP-1
expressing BAT in classic depots of white fat [7,8]. In light of these
observations, we compared BAT activities, long-lived catechol-
amine metabolites, i.e. plasma metanephrine and normetaneph-
rine concentrations, as well as body fat parameters in normal
subjects and patients with pheochromocytoma, a neuroendocrine
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Our present data demonstrate that BAT activity is strongly and
positively correlated with catecholamines concentrations in the
subjects, and is negatively related with their adiposity, especially
waist circumferences; suggesting an important role of adrenocep-
tor-UCP1 system in the regulation of active BAT and subsequent
central obesity in adult human.
Methods
Ethics statement
This study was approved by the Institutional Review Board of
the Rui-jin Hospital Affiliated to Shanghai Jiao-Tong University
School of Medicine and was in accordance with the principle of
the Helsinki Declaration II. The written informed consent was
obtained from each participant.
Subjects
From all pheochromocytoma patients diagnosed during 2007–
2010 at Shanghai Clinical Center for Endocrine and Metabolic
Diseases, fourteen have performed consecutive
18F-fluorodeox-
yglucose (
18F-FDG) PET/CT whole-body scans. These patients
were confirmed by postoperative pathology. Fourteen age- and
BMI-matched healthy volunteers were also recruited for the study.
Data on age, sex, weight, height, fasting glucose, triglyceride,
cholesterol and thyroid hormone levels, medication use were
obtained for all subjects.
In the present study, plasma catecholamines level was represent-
ed by its long-lived metabolic products, i.e. plasma metanephrine
(MN) and normetanephrine (NMN) created by action of catechol-
O-methyl transferase on epinephrine and norepinephrine, deter-
mined by reverse-phase high-performance liquid chromatography
(HPLC) (Agilent 1100 series, Santa Clara USA) with electrochem-
ical detection (ESA-A Dionex Company, Chelmsford USA) as
previously described [9,10]. In our earlier study on 40 healthy
volunteers, plasma concentrations of MN ranged between 18.8 and
78.2 ng/L (mean 39.9616.6 ng/L), and NMN between 17.5 and
118.8 ng/L (mean 61.1625.6 ng/L). Thus, using the upper 2SD as
cut-off points, the subjects can be classified into three groups: 8
pheochromocytoma patients with high total metanephrine (TMN:
MN+NMN) (.185 ng/L, Group A), 6 pheochromocytoma
patients with normal TMN (,185 ng/L, Group B) and 14 normal
controls (Group C).
Brown adipose tissue activity by PET/CT scan
All of the subjects were studied in the morning after an
overnight fast beginning around 10 p.m. the night before. The
blood glucose concentration of each subject was controlled under
the level of 7.4 mmol/l before
18F-FDG (4.44–5.55 MBq/kg) was
injected intravenously. They were kept under thermoneutral
conditions (23–25uC) for at least 1 h after injection. Later the
18F-
FDG PET/CT scans were performed with a GE Discovery
STE16 integrated PET/CT scanner combining the ability to
acquire CT images and PET data of the same subject in one
session. The whole-body CT data were acquired by a continuous
spiral technique on a 16-slice helical CT (gantry rotation speed,
0.8 s per rotation, 140 KV, 17.5 mm per rotation table speed). All
CT scans were obtained with 3.75 mm thick axial sections and the
axial field of view was 15.6 cm. Subsequently, a positron emission
scan was performed from the thigh to the head at a 3 min/bed
position speed. The attenuation-corrected PET images, combined
with CT data, were reconstructed by an ordered-subset expecta-
tion maximization algorithm.
PET and CT images were coregistered and analyzed by a
GEAW workstation with PET/CT Volume Viewer software. Two
experienced blinded observers assessed the FDG uptake, partic-
ularly in both sides of the neck and paravertebral regions, by
visually judging the radioactivity greater than background [1]. In
parallel, the activity of BAT was quantified by mean standardized
uptake values (SUVmean ? g/ml) [4] which is an automatic
method based on GE AW workstation [11]. The standardized
uptake values, defined as the activity per milliliter within the
region of interest divided by the injected dose in megabecquerels
per kilogram of body weight was determined [4]. Calculations
were performed using PET/CT Volume Viewer software.
Visceral/subcutaneous fat areas and waist
circumferences
Abdominal fat distribution was examined at the umbilicus level
in the supine position using CT, according to the previously
described procedure [12]. The intra-abdominal visceral fat areas
(VFA), subcutaneous fat areas (SFA), and waist circumferences
(WC) were measured with image analysis software package (Fat
scan, N2 system, Osaka, Japan). Visceral/total fat areas (V/T) was
calculated as VFA/(VFA+SFA) 6100%.
Statistics
Statistical analysis was performed with SAS 9.2 (SAS Institute,
Cary NC). All continuous parameters were summarized as
means6SD, and all categorical parameters were summarized as
proportions. To compare between-group differences, robust
ANOVA was performed to compare difference in BAT activity
between groups [13]. A conventional linear regression model was
used to explore the association between BAT activity and other
parameters, such as TMN, BMI, VFA, SFA, V/T and WC. To
minimize the impact of outliers on regression estimators, robust
regression analysis was performed to identify factors that are
independently associated with BAT [13]. The P-values reported
were two-sided. A P-value of less than 0.05 indicated statistical
significance.
Results
Information on all pheochromocytoma patients to Shanghai
Clinical Center for Endocrine and Metabolic Diseases between
2007 and 2010 was recorded and collated on an intra-hospital
database. This database contained information on clinical details,
biochemical examination, imaging records and pathology results.
Based on this database, we extracted records of all patients with
pheochromocytoma that have performed PET/CT whole-body
scans. All of the patients presented clinical findings of hyperten-
sion, associated with positive results in PET/CT, and finally
confirmed by post-operative pathology. Among them, eleven cases
(80%) were adrenal pheochromocytoma and three cases (20%)
were from extra-adrenal chromaffin tissues. Two patients were
reported as metastatic disease. Plasma total metanephrine (TMN)
levels were significantly higher in eight patients with pheochro-
mocytoma (Group A: 240361189 ng/L, Table 1) than the other 6
patients (Group B: 122612 ng/L, Table 1) and normal subjects
(Group C: 116.468.1 ng/L, Table 1). Serum fasting glucose,
triglyceride, cholesterol and thyroid hormone levels (FT3, FT4)
were comparable within three groups (Table 1). None of the
subjects have taken ß -adrenergic blockers at the time of PET scan.
On the fused PET/CT images, the brown adipose tissue was
located not in muscle tissue but in fat tissue, within the neck,
supraclavicular and paravertebral region (Fig. 1D) as previously
reported [4,5,6]. Six out of eight patients from Group A had
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patients had no
18F-FDG uptake in areas of adipose tissue. These
two subjects either had the highest BMI, total fat areas or lowest
TMN levels. On the contrary, there was no detectable brown
adipose tissue in any of the subjects with normal TMN
concentrations irrespective of their pheochromocytoma disease
background (Fig. 1B-C, Table 1). Similar results were observed
when the mean BAT activity was taken into account: it was sig-
nificantly higher in Group A patients (6.762.1 SUVmean? g/ml)
than that in Group B (0.460.04 SUVmean? g/ml, p,0.0001) and
Group C (0.460.03 SUVmean?g/ml, p,0.0001) (Table 1). No
significant difference in BAT activity was observed between Group
B and Group C that presented comparable TMN levels (Table 1).
These data indicate that circulating catecholamines level, rather
than the disease itself, might determine BAT activity in
pheochromocytoma patients.
We further performed a conventional linear regression to
explore the association between BAT activities and TMN
concentrations in our subjects. For the first time, we demonstrated
a strong and significantly positive correlation between BAT
activities and TMN levels (both in log scale; R=0.83,
p,0.0001, Fig. 2). These results indicate that BAT activity can
be strongly induced by increasing adrenergic input in adult
humans, such as in the case of patients with pheochromocytoma.
It has been reported that the amount of brown adipose tissue is
inversely related to body mass index (BMI) in adult human [4,6].
In the present study, we included not only BMI but also other
parameters, such as visceral fat areas, subcutaneous fat areas,
visceral/total fat areas and waist circumferences, which measured
abdominal fat volume and distribution [12]. Pearson correlation
test revealed that LogBAT was negatively correlated with
BMI (R=20.47, p=0.010), visceral fat areas (R=20.39,
p=0.044), visceral/total fat areas (R=20.52, p=0.0043), waist
circumferences (R=20.43, p=0.019), but not with subcutaneous
fat areas (R=20.15, p=0.45). In the next step, robust regression
analysis was performed to identify factors that were independently
associated with BAT (log scale) [13]. Among age, sex, BMI, VFA,
SFA, V/T, WC, and TMN examined, only TMN (R=0.81,
p,0.0001) and waist circumferences (R=20.009, p=0.009) were
found independently associated with BAT activity (Table 2).
Discussion
It was normally believed that brown fat is present only in fetuses
and infants and diminishes in adults [2], however recent studies
have clearly demonstrated that adults do possess metabolically
active brown fat which can be detected by PET/CT imaging and
be stimulated by cold exposure [4,5,6]. Moreover, the observation
that the amount of BAT is inversely correlated with body mass
index [1,4,5], have led to an increased interest in the potential
importance of BAT in regulating body weight and as a potential
target for treating obesity [1,4,5,6]. With this knowledge of BAT,
targeted therapies are under study, by either induction of already
available BAT (with ß-adrenergic activator) [14,15] or changing
the genetic structure for differentiating tissue from the preadipo-
cyte phase to BAT [16,17].
From studies performed in vitro, catecholamines have been
suggested to play a prime role modulating not only brown
preadipocyte proliferation, mature brown adipocytes differentia-
tion, but also their apoptosis [2]. The present study now shows that
the circulating total metanephrines, long-lived catecholamines
metabolites levels and BAT activities were simultaneously elevated
in patients with pheochromocytoma under thermoneutral condi-
tions. These data suggest that the catecholamines such as
epinephrine and norepinephrine might stimulate BAT activity,
which is supported by the following evidence. First, 6 of 14 patients
Table 1. Characteristics of the subjects.
Characteristic Pheochromocytoma patients Normal subjects
High TMN
(Group A, N=8)
Normal TMN
(Group B, N=6)
Normal TMN
(Group C, N=14)
Age (Yr) 37.864.9 45.864.8 46.962.4
Detectable Brown-adipose-tissue 6/8 0/6 0/14
Brown-adipose-tissue
#
##
#activity (SUVmean?g/ml)
#
6.762.1 0.460.04* 0.460.03*
Total metanephrines
ˆ
(TMN, ng/L)ˆ
240361189 122612* 11668.1*
Body mass index{ 22.461.0 23.661.6 23.960.6
Visceral Fat Areas{ 50.769.2 91.5634.3 85.7613.6
Subcutaneous Fat areas{ 161.5615.5 217.5637.1 127.1612.3
Waist circumferences{ 83.863.3 93.665.7 86.462.0
Fasting blood glucose (mM) 5.660.5 5.360.4 5.360.2
Triglyceride (mM) 1.360.3 1.360.2 1.560.3
Cholesterol (mM) 4.760.2 4.860.5 4.460.3
Free T3 (pM) 4.160.2 3.960.4 4.060.2
Free T4 (pM) 12.560.5 12.360.7 13.560.5
#Brown adipose tissues activity was quantified by mean standardized uptake values (SUVmean ? g/ml) by PET/CT.
ˆTotal metanephrines were calculated as metanephrine (MN) plus normetanephrine (NMN).
{Body mass index was calculated as weight in kilograms divided by height in meters squared.
{Visceral fat areas, subcutaneous fat areas and waist circumferences were examined at the umbilicus level in the supine position using CT.
*compared to pheochromocytoma patients with high TMN (Group A), p,0.001.
doi:10.1371/journal.pone.0021006.t001
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adiposetissueofthesupraclavicularandparaspinalregions,whereas
no detection was found in normal controls. Second, all the BAT
positive patients were presenting elevated TMN levels, while none
of the patients with normal TMN had brown adipose tissue
detections, indicating that BAT activity is hormone-dependent,
rather than disease-specific. Third, we were the first to provide a
strong and positive correlation between BAT activity and
circulating TMN concentration (r=0.83, p,0.0001), thus un-
doubtedly demonstrated that BAT activity could be activated
adrenergically in humans. Fourth, TMN was the strongest predictor
of BAT activity, independent of other influencing factors such as
age, sex, BMI, and fat distribution. The present finding is consistent
with several earlier case reports by nuclear medicine physicians: an
increased glucose uptakewas observed ina 50-year-old male patient
with adrenal pheochromcytoma [18] and a disappearance of
prominent FDG uptake in BAT was found in a 25-year-old woman
withmediastinal pheochromocytoma afterthetumorresection[19].
A more detailed finding by Hadi et al reported 26 (27.0%) of 96
patients with known or suspected pheochromocytoma showed BAT
evaluated with (18)F-FDA or (18)F-FDG PET/CT [20]. However,
Figure 1. BAT activity can be detected by PET/CT in pheochromocytoma patients with elevated TMN concentration. The results of
PET–CT scanning in pheochromocytoma patients were compared to healthy subjects. Panels A-C shows images of the neck and upper thoracic
region of individuals with variable physiologic uptake and distribution of
18F-fluorodeoxyglucose (
18F-FDG) in adipose tissue. A front and a side scan
were shown individually. The images in row (A) are from three pheochromocytoma patients with high total metanephrine (TMN) levels (Group A).
Three pheochromocytoma patients with normal TMN concentrations from Group B and three healthy subjects from Group C were shown in row (B)
and (C) accordingly. A PET scan in the transverse plane (Panel D, left) shows the areas of brown adipose tissue (arrow), and a CT scan (Panel D, middle)
confirms the areas of brown adipose tissue (arrow) according to fat density and location. Fusion of the PET and CT scans (Panel D, right) shows that
18F-FDG uptake is localized in fatty tissue (arrow).
doi:10.1371/journal.pone.0021006.g001
Figure 2. Activities of brown adipose tissue in relation to total
metanephrine levels. For all subjects, the activities of brown-
adipose-tissue (BAT) were plotted against their total metanephrine
(TMN) values following Log transformation. Statistical analysis was
performed using Pearson correlation test: R=0.83, p,0.0001.
doi:10.1371/journal.pone.0021006.g002
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betweencatecholamines levelsand BATactivation.Taken together,
brown fat in adult human can be activated and can expand quite
massively due to catecholamines over-secretion, proving a central
role of adrenergic activation in BAT regulation.
It is well established that catecholamines-mediated effects on
energy expenditure and alterations in the efficiency of carbohydrate
metabolism are possible mediators of changes in body weight.
Catecholamines can increase fat lipolysis and reduce adipogenesis or
the creation of new fat [21] and this effect is attenuated in the
subcutaneous adipose tissue of obese subjects [22,23]. Our finding
that catecholamines-associated brown adipose tissue activation
might provide additional explanation on the impact of these
hormones on body weight control. Early evidence for BAT as a
tissue affecting adiposity in rodents came from animals with
surgically denervated interscapular BAT [24] or transgenic mice
with 60–70% reduction in BAT mass [25,26]: these animals
accumulated abnormal amounts of body fat. Consistent with several
recent studies on adult human [1,4,5], our data found an inverse
relation between BAT activity and adiposity. Considering a key role
ofadrenergicinputonBATregulation,itisrelevantinourstudythat
brownadiposetissue,whichisactivatedbycatecholamines,resultsin
burning large amounts of abdominal fat through oxidation in
mitochondria. In addition, catecholamines-induced trans-differenti-
ation of existing white fat cells to brown adipocytes [2] can not be
neglected.In mice and rats, exposure to cold orß-adrenergic agonist
induces the appearance of brown adipocytes in traditional white fat
pads [27,28,29]. In patients with pheochromocytoma, the induction
of UCP-1 expression was observed in intra-abdominal adipose tissue
[30,31]. Although some plasticity seems to exist between the white
and brown adipocytes, the extent of such shift in humans and the
molecular mechanisms governing these remain unknown. Another
interesting point to be noted is that by using abdominal fat areas
measurement, we found that BAT was inversely related with central
obesity parameters, i.e. visceral fat areas, visceral/total fat areas,
waist circumferences of the subjects. On the contrary, subcutaneous
fat areas did not show significant correlation. Moreover, by robust
stepwise regression we identified waist circumferences, a parameter
of central obesity [32], one of the two significant and independent
predictors of BAT activity besides TMN. It has been reported that
waist circumference correlates highly with visceral mass and has
been shown to predict metabolic risks and coronary heart disease
better than other indices of adiposity including BMI [33]. Based on
the present observations, we propose that brown adipose tissue
might play a more pronounced role on protecting central obesity
and reducing metabolic syndrome. Studies can thus be planned to
investigate the impact of BAT activity on central obesity and
metabolic risk in larger population.
In summary, in the present study, the use of
18F-FDG-PET/CT
shows that brown adipose tissue is strongly activated in adult
human with elevated circulating catecholamines concentration.
Waist circumferences preferentially than BMI, is inversely
correlated with the amount of brown adipose tissue, suggesting a
possible role of brown adipose tissue in protecting against central
obesity. Our result may highlight again adrenoceptor-UCP1
system in pharmacological approach to obesity treatment, which
has repeatedly been confirmed in experimental animals
[14,15,34,35], but not yet approved in humans. The recent
evidence that there is a significant amount of brown adipose tissue
expressing ß 3-adrenergic receptor in many adult humans, and our
current finding that their activity can indeed be stimulated by
adrenergic input and is inversely related with visceral fat volume,
might offer new hope in searching for intriguing target for the
control of whole-body energy balance and obesity.
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